Regenerative capacities vary enormously across the animal kingdom. In contrast to most cold-blooded vertebrates, mammals, including humans, have very limited regenerative capacity when it comes to repairing damaged or degenerating tissues. Here, we review the main mechanisms of tissue regeneration, underlying the importance of cell dedifferentiation and reprogramming. We discuss the significance of cell fate and identity changes in the context of regenerative medicine, with a particular focus on strategies aiming at the promotion of the body's self-repairing mechanisms. We also introduce some of the most recent advances that have resulted in complete reprogramming of cell identity in vivo. Lastly, we discuss the main challenges that need to be addressed in the near future to develop in vivo reprogramming approaches with therapeutic potential.
Introduction
Some organisms are able to successfully regenerate entire parts of their bodies, while others can suffer permanent damage following even a mild injury (Fig. 1) . Generally speaking, the term regeneration defines a process finalised at the re-establishment of the physiological and morphological functions of damaged tissues and/or organs. Regenerative processes can be classified into two broad classes of events, namely morphallatic and epimorphic [1, 2] . On the one hand, morphallatic regeneration involves migration of stem cells to the damage site, where they differentiate into tissue-specific cell types; this process is employed, for instance, by hydra, and does not involve a proliferative stage. On the other hand, proliferation is crucially important in epimorphic regeneration, which can depend on either pre-existing stem/progenitor cells (e.g. planaria) or on dedifferentiation of resident tissue cells (e.g. salamanders).
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of resident stem cell pools [3] [4] [5] . However, this is limited to a few organs with physiological cell turnover, such as the skin, the blood system and the gut. In the context of tissue injury and degeneration, most mammalian tissues are endowed with very limited regenerative capacity. Indeed, mammals seem to have "lost" the potential for extensive organ repair, and their ability to self-regenerate following injury and disease is extremely restricted.
Despite the collective effort of the scientific community, we still need to satisfactorily explain why mammals are unable to regenerate a missing limb or repair a damage organ. Therefore, before proceeding with further discussions, it is important to understand what are the mechanisms that underlie the ability to extensively repair damaged tissues in early vertebrates.
Mechanisms of tissue regenerationthe importance of cell dedifferentiation
The broad regenerative potential that characterises amphibians and other cold-blooded vertebrates can be ascribed to the dedifferentiation of resident cells located in close proximity of the injury site. In the case of damage to newts' lenses, for instance, pigmented epithelial cells of the dorsal iris dedifferentiate back to a progenitor state, temporarily re-enter the cell cycle and eventually redifferentiate to generate a new, functional lens [6] [7] [8] . Importantly, the newly generated tissue is indistinguishable from the lenses of younger animals. This regenerative capacity remains unchanged throughout the entire lifespan of the organism, Fig. 1 . Spectrum of regenerative potential in the animal kingdom. Platyhelminthes (e.g. planarians) are found on the left-end of the regeneration spectrum, as they are characterised by outstanding regenerative capacities. For instance, an entire planaria can be formed starting from a tissue fragment that is only 1/279th of the original body size [151, 152] . Amphibians also possess remarkable regenerative capacities [153] . These observations date back more than 200 years, when Lazarro Spallanzani reported for the first time that salamanders were able to replace not only damaged organs, but also entire limbs and tails [146] . Similarly, newts can fully regenerate their lenses following complete lentectomy [147] . Regenerative potential is also present in animals from other phyla, including Chordates such as ascidians and zebrafish. Zebrafish, in particular, can completely regenerate their heart following amputation of up to 20% of the ventricle [148, 149] . It is also able to completely regenerate damaged retinal tissue [12] . Potential for retinal regeneration is also maintained in birds, even if only partially. In fact, the avian retina can be efficiently regenerated in the early postnatal period; this capacity, however, is lost as the animal ages [154] . Mammals are found on the right-(and lower)-end of the regeneration potential spectrum. In fact, the liver is the only mammalian organ that can be endogenously repaired following injury, regaining sufficient function to lead a normal life. Most of the other organs, instead, are endowed with very limited regenerative capacity.
regardless of the number of injuries suffered [9] . The occurrence of dedifferentiation has also been described and characterised for zebrafish cardiomyocytes and M€ uller glia cells (MGCs), in the context of heart and retina repair respectively [10] [11] [12] .
Following tissue injury in mammals, however, dedifferentiation does not frequently occur. Indeed, years of intense investigations and debates have culminated in the wide acceptance of the hypothesis that the dedifferentiation step might represent one of the major differences between the regeneration that occurs in salamander and that of other warm-blooded vertebrates, including mammals.
Mechanistically, cell dedifferentiation is dependent on the occurrence of numerous distinct events. In particular, inactivation of the tumour suppressor retinoblastoma protein (pRB) plays a crucially important role [13] (Fig. 2) . In fact, in addition to regulating exit from quiescence, pRB is also implicated in the maintenance of cell identity. Indeed, its inactivation can render mammalian cells prone to dedifferentiation, even when proliferation is impeded [14, 15] . It is, however, important to specify that proliferation and dedifferentiation are independent processes, and re-entry into the cell cycle is not necessarily associated with loss or redefinition of cell identity.
It is also interesting to note that, in mammals, pRB loss alone is not sufficient to induce dedifferentiation and/or re-entry into the cell cycle [16] . This is most likely due to the INK4b-ARF-INK4a locus, which, in  addition to p15  INK4b and p16  INK4a CDK inhibitors,  encodes a protein called ARF (or p14 ARF , from alternate reading frame). In the absence of pRB, ARF can activate compensatory mechanisms that lead to p53-mediated growth arrest [17] (Fig. 2) . In support of this hypothesis, combined inactivation of both pRB and ARF has been shown to stimulate dedifferentiation and proliferations of mammalian muscle cells [18] . Indeed, ARF is not present in many regenerating vertebrates, which could make them intrinsically better at responding to dedifferentiation signals. This could explain, at least partially, why mammalian tissues have lost their self-repairing capabilities [18] . It could even be speculated that evolution has strongly disfavoured fate changes in mammalian cells. From an evolutionary point of view, this could be explained by the need for a trade-off between maximising tissue repair and minimising the risks of malignant cellular transformation. In fact, pRB has been implicated uncountable times in the development and progression of various types of tumours. In other words, ensuring maintenance of the quiescent state (even if at the expense of regeneration) is probably more "valuable" and advantageous for the overall survival of the organism. Despite promising and intellectually satisfying, however, these explanations await further confirmation, and currently remain on a rather speculative level.
Several other questions also remain to be addressed. For instance, it has not been clearly elucidated yet why exposure to an extract derived from regenerating newt limbs can induce proliferation and a certain level of dedifferentiation in mammalian myotubes [19] . Indeed, this observation introduces the possibility that some extrinsic signals might also be released following injury in amphibians, but not in mammals. Such signals could be context-specific, meaning that the local microenvironment could also play a crucially important role. This could explain INK4b and p16
INK4a
), pRB is found in its active, hypophosphorylated state. Active pRB blocks proliferation by sequestering members of the E2F family of transcription factors. It can also recruit histone deacetylases (HDAC) to further repress expression of cell cycle genes. Additionally, pRB can enhance recruitment of lineage-specifying transcription factors (e.g. MyoD in skeletal muscle cells), promoting expression of differentiation genes and the stable maintenance of a specific somatic cell identity [156, 157] . (B. Proliferating Cells): In proliferating cells, CDK-inhibitors are inactive, which allows the cyclinD-Cdk4/6 complex to phosphorylate and inactivate pRB. pRB inactivation causes exit from quiescence, as E2F transcription factors are available to drive expression of genes involved in DNA replication and entry into S-phase of the cell cycle [155] . Moreover, independently from the induction of proliferation, pRB inactivation can lead to a decrease in the expression of differentiation genes, thereby favouring dedifferentiation. In other words, cellular dedifferentiation and proliferation can both be favoured by pRB inactivation. After passing this checkpoint, a particular cell is committed to a single round of division. (C. Cell Cycle Arrest): However, if DNA damage occurs, ATR and ATM protein kinases are activated [158] . They phosphorylate checkpoint kinases 1 and 2 (Chk1 and Chk2), which, in turn, phosphorylate and activate p53. Active p53 drives expression of p21, which induces cell cycle arrest by blocking activity of Cyclin/Cdk complexes. p53 also activates the DNA repair machinery, and, if DNA damage is too extensive to be repaired, it eventually induces cell apoptosis or senescence [159] . pRb and p53 operate as part of a larger network that is wired for functional redundancy. This means that dedifferentiation and/or re-entry into the cell cycle cannot be induced simply by inactivating pRB. Indeed, in the absence of pRB, oncogenic stimulation can activate ARF, which leads to p53-mediated growth arrest. In fact, active ARF can inactivate mouse double minute 2 homolog (mdm2), a E3 ubiquitin-protein ligase that normally stimulates p53 degradation [160] .
why local factors (such as neurotrophic factors, ECM proteins and hormones) allow partial dedifferentiation of Schwann cells and not, for instance, of cardiomyocytes [20] . Indeed, an increasing number of reports are now showing that some mammalian cell types can be induced to dedifferentiate upon stimulation with specific signals and/or treatments. As an example from our field of interest, damage-induced dedifferentiation and proliferation of MGCs in the mammalian retina can be promoted via treatment with mitogenic factors, such as insulin, epidermal growth factor (EGF) and Wnt3a [21] [22] [23] [24] .
Collectively, these observations are opening up new and provocative questions regarding the potential applicability of therapeutic methods that can promote changes in cell identity and enhance endogenous regeneration.
Cell fate and reprogramming
In the classical view of development, the differentiated state of a cell was believed to be terminal and irreversible. This concept has been best exemplified by Conrad H. Waddington's description of the epigenetic landscape (Fig. 3) [25]. Building upon Waddington's original idea, during the 1960s, John Gurdon successfully cloned a frog via transplantation of a somatic nucleus from the animal's intestine into an oocyte [26] . Gurdon showed for the first time that the identity of differentiated cells could be reversed. His work was followed by the generation of Dolly the sheep [27] , which confirmed that the epigenetic state of somatic cells could be reprogrammed to an embryonic pluripotent state.
Nowadays, in addition to nuclear transfer, differentiated cells can be artificially induced to revert to a pluripotent state via one of two mechanisms: (a) cell fusion with embryonic stem cells (ESCs) [28] ; (b) transduction with specific cocktails of transcription factors, resulting in the generation of the so-called induced pluripotent stem cells or iPSCs [29, 30] . Furthermore, the establishment of ESCs cultures in the 1980s [31, 32] has allowed for extensive in vitro investigation of mechanisms controlling pluripotency, contributing to the unravelling of puzzling concepts such as potency, lineage-commitment and cell fate. Actually, combining what is being learnt from ESCs/iPSCs-based in vitro studies with the investigation of in vivo regenerative mechanisms could potentially help us gain an in-depth understanding of repair processes, opening up the possibility of designing successful strategies for the replacement of lost and/or damaged cells, which is the fundamental purpose of regenerative medicine.
Regenerative medicine
Regenerative medicine aims at the restoration of physiological function in organs and tissues not normally prone to injury-induced repair. Over the past few decades, increasing time and effort have been invested in the development of approaches to achieve such goal. In our view, however, two are the main strategies that could eventually be employed in the clinical setting: cell therapy and stimulation of endogenous regeneration.
Here, after briefly discussing some of the key aspects of cell therapy, we will focus on strategies aimed at the promotion of endogenous repairing mechanisms, with particular emphasis on their advantages, their drawbacks and the challenges that need to be addressed.
Cell therapy
Cell therapy is based on transplantation into the injured site of either stem/progenitor or differentiated cells. It is almost unanimously considered a promising strategy for the repair of damaged organs. Indeed, the development and optimisation of detailed, fine-tuned protocols have enabled us to generate iPSCs directly from accessible tissues of human patients. Additionally, both ESCs and iPSCs can be differentiated into organ-specific cells to be transplanted back to the patient [30, 33, 34] . Transplantation of iPSC-derived cells has been proven beneficial in rodent models of sickle cell anaemia [35] , Parkinson's disease [36] , diabetes [37] and spinal cord injury [38] . The possibility of transplanting adult stem cells is also being explored, with bone marrow derived cells being particularly promising candidates.
Regardless of the identity of the transplanted cells, cell therapy offers the advantage of an ex vivo expansion step, making it possible to obtain sufficient starting material to ensure adequate replacement of lost tissue. Furthermore, the use of patient-derived iPSCs and adult stem cells would introduce the possibility of autologous transplantation, reducing (even though not completely eliminating, as reviewed by Boyd et al. [39] ) the chances of immune rejection.
However, for the time being, cell therapy is still in its early stages, and it only works reliably for bone marrow replacement. Undoubtedly, it requires significant further development before being applicable to other organs of the human body. Indeed, cell therapy approaches are intrinsically associated with a number of limitations, including poor engraftment and poor functional integration. Moreover, standardised protocols for the derivation of uncontaminated clinicalgrade cells need to be established. Actually, ESC/ iPSC-based therapies can raise controversial concerns with respect to the risk of tumorigenesis [40] . Many of these limitations can be overcome by approaches targeting the endogenous regenerative potential of mammalian tissues and organs.
Endogenous regeneration
Stimulation of endogenous regenerative pathways could hold a tremendous potential as a therapeutic tool, offering numerous advantages over transplantation-based strategies.
To begin with, newly generated functional cells will be autologous by definition, eliminating the risk of immune rejection. Additionally, these cells would already be located in the vicinity of the injury, and they would most likely derive from the same (or a similar) cell type. This means that they would already be found where needed, and that they would be exposed to a local microenvironment that favours differentiation into the appropriate cell type. Furthermore, in vivo reprogramming is associated with lower risks of tumorigenesis [41, 42] , and with very few ethical issues and concerns. These kinds of approaches would also eliminate the need of strictly assessing the phenotype of the cells to be transplanted, with respect not only to gene expression, but also to chromatin state and functionality. In fact, reprogramming does not seem to be accompanied by a proper reset of the epigenome to a true ESC-like state. Consequently, some iPSCs retain Fig. 3 . The epigenetic landscape. The epigenetic landscape can be compared to a mountain with various valleys and several possible tracks leading to the bottom. In this analogy, cells are balls rolling down the side of such mountain. Cells at the very top of the mountain are found in a totipotent or pluripotent stage. Every time the ball meets a bifurcation, it has to commit to a choice, which will affect and limit its developmental potential, giving access to a more restricted number of developmental paths. This process continues until the ball reaches the bottom of the mountain, where it will remain in a stable valley, corresponding to its defined differentiated state. In contrast to what originally postulated, the identity of terminally differentiated cells can be induced to change via several processes: dedifferentiation, transdifferentiation, transdetermination and reprogramming. Dedifferentiation: The term dedifferentiation is intrinsically associated with lineage reprogramming, meaning that fully differentiated cells revert back to a less differentiated (and proliferative) stage from within their own lineage, without reaching pluripotency. Reprogramming: Reprogramming refers to the full restoration of pluripotency, up to a stage where cells can switch lineages and differentiate into any cell type; it could be seen as a case of extreme dedifferentiation, involving dramatic changes at the levels of both gene expression and epigenetic signatures. Transdifferentiation: Transdifferentiation describes the conversion of a fully differentiated cell of a given tissue lineage directly to one of a distinct lineage, without passing through a pluripotent intermediate. Transdetermination: Transdetermination describes the conversion of adult multipotent stem cells from their normal lineage to a closely related one [161] . So far, transdetermination has only been observed in the heapato-pancreatic system, most likely owing to the fact that the pancreas and the liver share a common developmental origin, with hepatic and pancreatic progenitors being derived from the same endodermal stem cells [162] . More specifically, upon transduction with the endocrine transcription factor neurogenin3 (Neurog3), hepatic progenitor cells were reported to generate, in the liver, insulin-producing cells that could rescue a mouse model of diabetes [161] . Transdetermination could also explain the reported presence of hepatocytes in the pancreas of rodents [163] , and the other cases of pancreatic cells located in the liver, previously thought to be the result of trandifferentiation events [164] [165] [166] .
memory of their previous epigenetic status, or some residual methylation reflective of the donor cells [43, 44] . This could explain why iPSCs derived from different tissues tend to preferentially differentiate along lineages close to the one from which they were originally derived [44] .
Promotion of the body's self-repairing mechanisms could be theoretically achieved in a number of ways that include: (a) activation of resident stem cells; (b) proliferation of uninjured residual tissue cells; (c) fate conversion of other, healthy resident cells in vivo [45] [46] [47] [48] . For instance, we have recently shown that, in the context of tissue damage, MGCs of the murine retina can dedifferentiate and convert into ganglion and amacrine neurons following fusion with endogenous bone marrow cells [49] . Indeed, in most tissues, endogenous repair is dependent on injury-induced progenitor cells that can undergo dedifferentiation, transdifferentiation and reprogramming (Fig. 3) .
Some mammalians tissues, however, also contain a reservoir of adult stem cells (ASCs) that can contribute to the maintenance of tissue homeostasis [50] . ASCs are normally quiescent, but they can become active if exposed to appropriate stimuli [51] . Indeed, upon injury, they can re-enter the cell cycle and differentiate into tissue-specific cell types [52] . This endogenous repair mechanism, however, is not sufficient to maintain organ integrity and ensure adequate functionality in the face of severe injuries.
In addition to stem cells, dedifferentiation, transdifferentiation and reprogramming events involving tissue-resident somatic cells can also play a central role in endogenous tissue regeneration (Fig. 3) .
Reprogramming cell identity in vivo
The power of cellular reprogramming and the fact that dedifferentiation seems to promote successful regeneration in mammals lead to wonder whether the generation of dedifferentiated or pluripotent cells can be achieved directly in vivo.
In this direction, it has been shown that cell reprogramming can be achieved within a living organism via induction of the four Yamanaka factors, namely Oct3/4, Sox2, Klf4 and c-Myc (OSKM) [53, 54] . These studies were based on the use of 'reprogrammable mice', in which OSKM expression could be induced with doxycycline. Doxycycline-mediated induction of OSKM resulted in the generation of NANOG-positive clusters of dedifferentiated cells in several tissues [53] . Analogously to the in vitro process, in vivo reprogramming involves substantial remodelling of chromatin organisation. This, in turn, is mediated by erasure of specific epigenetic marks, and de novo establishment of others. In particular, reprogramming cells undergo major rearrangements in heterochomatic regions, with an overall loss of centromeric clusters, and of H3K9 and H4K20 trimethylation [55, 56] . Profound changes in heterochromatin structure are also accompanied by improvements in the nuclear envelope architecture [57] and by telomere elongation [55, 56] .
However, it is important to discuss how most of the epigenetic changes described to date in the context of in vivo reprogramming also occur during cancer development [58] . Indeed, the very same epigenetic changes that drive reprogramming can increase the likelihood that a given cell would undergo tumorigenesis. Accordingly, sustained OSKM induction prevents the long-term survival of doxycycline-treated animals due to extensive dedifferentiation and malignant transformation in vital organs [53, 54] . Nonetheless, it is also important to note that reducing the temporal extent of OSKM-induction can induce partial cell reprogramming in vivo, while simultaneously preventing teratoma formation [57] . These findings have already been confirmed by various independent studies [59, 60] , suggesting that modulation of epigenetic remodelling may represent a valid strategy for the promotion of in vivo regeneration, without induction of tumorigenesis.
Further investigation showed that tissue damage is an important factor in the promotion of cellular reprogramming. In fact, OSKM induction induces extensive damage in most of the cells, which respond by becoming senescent [58] . Senescence is a protective cellular response associated with the secretion of a plethora of cytokines, which can promote tissue remodelling. These cytokines, and most notably interleukin-6 (IL6), can create a more permissive environment for the reprogramming of neighbouring cells [58] .
Importantly, in vivo-generated iPSCs are significantly different from in vitro-generated ones, showing an expression profile remarkably more similar to that of true ESCs. Actually, like ESCs, in vivo-derived iPSCs can efficiently contribute to the inner cell mass (ICM) when injected into morulas. In vivo iPSCs can also undergo trophectoderm lineage differentiation, showing some totipotency features that even ESCs do not display [53] .
These observations have been backed up by various independent studies, reporting case of in vivo reprogramming in multiple organs, including the liver [59, 61] and skeletal muscle [60] . Transient OSKM induction can also induce rejuvenation in a mouse model of progeria (i.e. premature ageing) without tumorigenic side effects [55] . Interestingly, in this study, full pluripotency was not achieved; however, pulses of OSKM activity were sufficient to extend animal lifespan and improve multiple hallmarks of ageing, including: (a) establishment of nuclear envelope architecture; (b) increase in stem cell populations in the muscle and hair follicles; and (c) proliferation of beta cells in the pancreas and satellite cells in the skeletal muscle [55] .
Collectively, these studies suggest that in vivo reprogramming could be beneficial for the functional maintenance of various tissues.
Importantly, in addition to OSKM induction, reprogramming can be accomplished by expression of specific cocktails of transcription factors, as discusses below.
Reprogramming in the central nervous system (CNS)
Glial cells are abundant in the CNS, and they possess a remarkable level of plasticity, being able to convert into functional neurons [61] [62] [63] [64] [65] . Under normal circumstances, glial cells are generally quiescent; however, they can re-enter the cell cycle following injury or other pathological conditions like stroke and neurodegenerative disease [66] . Indeed, tissue damage and the associated process of reactive gliosis favour dedifferentiation and identity changes [65] [66] [67] . Reactive gliosis, in fact, is associated with changes in the expression profiles of resident astrocytes, which acquire some of the hallmarks of neural stem cells, thereby becoming a good target for conversion into neurons [65, [68] [69] [70] .
In the uninjured mouse brain, Sox2 is sufficient to induce conversion of NG2 glia into neurons [71] , and conversion of astrocytes into proliferative neuroblasts [72] . These cells can be generated even in aged brains and do not undergo apoptosis. Although they generally fail to become electrophysiologically functional neurons on their own, these cells can be induced to acquire a more mature neuronal phenotype by various treatment, including exposure to epigenetic modulators (e.g. valproic acid) or neurogenic factors such as noggin, brain-derived neurotrophic factor (BDNF) and bone morphogenetic protein (BMP) [72] . Encouragingly, newly generated cells can functionally integrate into neural networks, which is of tremendous importance from a clinical and translational point of view [73] . Even transplanted astrocytes can be induced to become neurons in vivo when expression of specific reprogramming genes is activated [74] .
Extremely fine-tuned protocols have also been established to generate specific neuronal subtypes, including motor neurons [75] and dopaminergic neurons [76] [77] [78] [79] . For instance, Neurog2 or NeuroD1 can convert astroglia towards a glutamatergic neuronal fate, while Ascl1 or Dlx2 push the GABAergic fate instead [63] [64] [65] . In the context of tissue damage, Ascl1 has also been shown to induce a neurogenic state in mammalian MGCs [80, 81] , especially when combined with inhibition of a histone deacetylase [82] .
It is interesting to point out that splicing is also emerging as an important mechanism modulating reprogramming and regeneration. For instance, the splicing regulator poly-pyrimidine-tract-binding (PTB) protein can play a key role in the regenerative process [83] . PTB controls a network of microRNA that targets the protein complex built on RE1-silencing transcription factor (REST). The REST complex normally acts to repress expression of several neuronal-specific genes in non-neuronal cells. PTB downregulation activates a series of cascades that can induce non-neuronal cells (e.g. HeLa, MEFs) to transdifferentate into neurons in vitro. It would be interesting to test whether this holds true for reprogramming in vivo.
Reprogramming in the heart
Mammals possess some potential for heart regeneration. In fact, contrary to normal belief, human cardiomyocytes are constantly being renewed, with about 50% of the myocardial mass being replaced during a normal lifespan [84] . However, following injury, regeneration is almost absent, and scarring occurs instead. This is due to the inability of cardiomyocytes to efficiently dedifferentiate and re-enter the cell cycle.
Nonetheless, cardiomyocytes can be forced to reenter the cell cycle by: (a) overexpression of specific factors, for example FGF1, periostin or neuregulin1 [83, [85] [86] [87] ; (b) removal of different negative regulators, such as cyclin-dependent kinase inhibitor p27Kip1, pRB/p130 or p38 MAP kinase [15, 85, 88] ; (c) treatment with oncostatin M [87] . Interestingly, oncostatin M is an IL6-related cytokine, and its treatment is associated with improved cardiac function in the context of acute myocardial infarction and chronic dilated cardiomyopathy [87] .
In addition to cardiomyocytes, even adult cardiac fibroblasts have been reprogrammed to cardiac-like myocytes [89] . Even though this was originally achieved in vitro, the findings could be recapitulated in an in vivo model of coronary artery ligation [46, 47, 90] . Importantly, newly generated cells were found to be functional, showing spontaneous contraction, rhythmic calcium oscillations and evidence of electrical coupling [46, 47, 90] .
Reprogramming in the pancreas
Pancreatic exocrine cells have been reprogrammed in vivo to endocrine b-cells in rodents with streptozotocin-induced diabetes. This was originally achieved via adenoviral-mediated expression of three transcription factors (namely Neurog3, Pdx1 and Mafa), which induced direct cell transdifferentiation [91] . Newly generated cells were able to secrete insulin at levels comparable to those of endogenous b-cells, significantly improving glucose tolerance and ameliorating hyperglycaemia [91] . Interestingly, the identity of the cell of origin is extremely important, as the same combination of factors is unable to induce conversion into b-cells of other cell types (e.g. fibroblasts and skeletal muscle cells). Following severe b-cell loss, other endocrine cells can also spontaneously change their identity [92, 93] . For instance, some glucagon-producing a-cells were reported to transdifferentiate into insulin-secreting cells [92] . Such conversion potential did not seem to drastically decrease with ageing [93] , and robust transdifferentiation correlated with improved blood glucose levels and reduced dependence from exogenous insulin [92, 94] . Intriguingly, reprogrammed b-cells continued expressing some a-cell specific genes, indicating that functional transdifferentiation does not necessarily requires complete repression of the starting transcriptional programme [92] . Moreover, such transdifferentiation routes can be bidirectional, as b-cells can also be converted to a-cells in vivo [95, 96] . Similarly, both acinar cells [97] and somatostatin-producing d-cells [93] can become b-like cells. Acinar cells, in particular, can be converted into b-like, glucose-responsive cells following exposure to EGF and CNTF, which activates the endocrine progenitor transcription factor Neurog3 [97] . This opens up the possibility to convert cells via transient cytokine exposure rather than viral delivery of exogenous transcription factors [97] .
Reprogramming mediated by bone marrow-derived cells (BMDCs)
Haematopoietic stem cells (HSPCs) are the best characterised stem cells of the adult organism. They were isolated from the bone marrow in the 1980s [98] and found to be able to differentiate into all the lineages of mature blood cell types. Indeed, a single transplanted HSC can repopulate the entire haematopoietic system of lethally irradiated animals [99, 100] . Then, in the late 1990s, some studies started to indicate that BMDCs could possess a wider plasticity than previously postulated, being able to generate multiple lineages other than blood (hereinafter, the term BMDCs will refer to total bone marrow unless otherwise specified). For instance, some transplanted adult mouse BMDCs were found to adopt a neural phenotype in the CNS [101] . Similarly, lineage-depleted (Lin À ) HSPCs transplanted in rodent models of ischaemia and myocardial infarction were reported to mobilise to the heart and transdifferentiate into cardiomyocytes and endothelial cells, thereby promoting functional repair [102, 103] . Even though these events occur with an extremely variable and generally low frequency, they have been observed in numerous independent studies and in multiple tissues, including: epithelia, skin and lung epithelium [104, 105] ; endothelium [102, 106] ; heart [102, 103] ; cardiomyocytes and skeletal muscle [99, [107] [108] [109] [110] ; liver [105, [111] [112] [113] [114] ; kidneys [115, 116] ; pancreas [117] ; CNS neurons [101, [118] [119] [120] .
However, it is important to stress that only a handful of these studies have characterised the functional relevance of in vivo cell fate conversion [102, 103, 112, 116] . Most of the other investigations reported the observation, but did not provide evidence of functional readout.
Cell fusion-mediated reprogramming and regeneration
Cell fusion is a developmentally important process. As a matter of fact, our own life starts with the fusion of our mother's ovum and our father's spermatozoa during fertilisation. Cell fusion is also involved in the development of muscle, bone, and placenta [121, 122] , and in the formation of multinucleated giant cells in response to chronic infections and tumours [123] . The molecular mechanisms involved in membrane fusion are still largely unknown [121, 122] . However, it is becoming increasingly clearer that cell fusion events can induce cell plasticity, thereby contributing to tissue regeneration [124, 125] .
Since the vast majority of reported fusion events in vivo involved BMDCs, we decided to focus on BMDC-mediated in vivo regeneration. Fusion of recruited BMDCs with terminally differentiated tissue cells can induce cell dedifferentiation and proliferation, representing a regenerative mechanism alternative to transdifferentiation [126, 127] .
Indeed, BMDCs have been reported to fuse with several types of somatic cells (Fig. 4) .
Cell fusion-mediated regeneration in the central nervous system (CNS)
Cell fusion events have been observed in the CNS. For instance, postmortem biopsies of women who had received a sex-mismatched BM transplant revealed the presence of tetraploid, Y chromosome-positive (XXXY) Purkinje neurons in the brain [119] . These findings were also confirmed in animal models. More specifically, transplantation of GFP-expressing BMDCs in irradiated mice led to the generation of a few GFP-positive BMDC-Purkinje neurons heterokaryons, indicating that BMDCs could contribute to adult neuronal circuits through cell fusion [120] .
The overall frequency of fusion events is quite low, but it seems to be significantly increased during chronic inflammation, degeneration and injury [49, 128, 129] . In fact, Johansson and colleagues showed that, in the context of severe dermatitis or autoimmune encephalitis, the frequency of fusion between BMDCs and Purkinje neurons was 10-to 100-fold higher than previously reported [119, 120, 130] , resulting in the generation of hundreds of fused heterokaryons [128] . This could be explained by the fact that neuropathology is associated with a significant enhancement of the chemokine-mediated recruitment and engraftment of BMDCs, especially around the damage site [118] . Microglial cells, astrocytes and neurons of the CNS constitutively express a variety of chemokines, which are involved in migration, differentiation and proliferation of glial and neuronal cells. Such constitutive expression is increased in the presence of inflammatory mediators, released in the context of acute and chronic conditions [131] .
Indeed, transplanted Lin À HSPCs have also been shown to fuse with glial cells in two distinct models of Parkinson's disease [132] . The resulting hybrids generated new mature astroglial cells, able to secrete neurotrophic factors (such as Wnt1), which, in turn, could prevent degeneration of some dopaminergic neurons [132] . Both endogenous [49] and locally transplanted [129, 133] Lin À HSPCs can also fuse with resident
MGCs of the retina. Resulting hybrids undergo partial dedifferentiation, re-enter the cell cycle and then rapidly commit to the neuroectodermal lineage, eventually differentiating into mature retinal neurons [129, 133] . Importantly, BMDC-MGC hybrids can contribute to the regeneration of the damaged retinal tissue [129, 133] . Interestingly, retinal injury or degeneration (and, most likely, the associated inflammatory environment) are essential for cell-hybrid formation in vivo [49, 129, 133] .
Cell fusion-mediated regeneration in the liver
Cell fusion events have been extensively shown to contribute to liver regeneration [113, 130, [134] [135] [136] . Actually, BM-derived hybrids are essential to trigger efficient liver regeneration after injury. Accordingly, regeneration is severely impaired when BMDC recruitment is impeded, or BMDC-hepatocytes hybrids are genetically ablated [136] . Interestingly, BMDC transplant in mice lacking the Fah enzyme (Fah
, a model of tyrosinemia type I) resulted in restored expression of the wild type gene in some hepatocytes [112] . More specifically, Lagasse and colleagues isolated and transplanted the so-called KTLS (c-kit high , Thy low , Lin
) fraction which is highly enriched for long-term repopulating HSC activity. This correlated with a rescue of the biochemical function of the liver [112] . Originally, Fah + hepatocytes were proposed to derive from BMDC transdifferentiation. However, convincing evidence has now shown that, during hepatic degeneration, cell fusion represents the main source of BM-derived hepatocytes [113, 114] . In fact, Fah + cells were found to express both donor and host genes [113] , and southern blot analysis revealed that hepatocytes in the liver were heterozygous for alleles unique to the donor marrow [114] .
Importantly, these studies have shown that fusion with transplanted BMDCs could be used to deliver wild-type alleles to tissue cells with recessive mutations, thereby representing a valuable strategy for the correction of genetic defects.
Cell fusion-mediated regeneration in the skeletal muscle
Transplanted BMDCs have been reported to migrate into areas of muscle degeneration in mice lacking dystrophin (Mdx À/À , a model of Duchenne Muscular Dystrophy). BMDCs were found to differentiate into myogenic cells, thereby contributing to the regeneration of damaged fibres either when unfractionated bone marrow cells [109] or lineage-depleted HSPCs were transplanted [110] . Once again, cell fusion rather than transdifferentiation seems to account for the observed cell identity changes. In fact, Y chromosomepositive muscle fibres were found in female animals that had undergone sex-mismatched BM transplantation [137] . Importantly, the presence of the Y chromosome correlated with restored dystrophin expression [137] . BMDC fusion with the skeletal muscle has been also reported in human patients with Duchenne muscular dystrophy [138] . More specifically, muscle biopsies from a female patient who had received a BM-transplant from a male donor showed that Y-containing nuclei were present within muscle myofibres, even 13 years after transplantation [138] .
Challenges for in vivo reprogramming approaches
Recent years have witnessed an explosion of interest in regenerative medicine and, more specifically, in approaches aimed at boosting the endogenous regenerative capacities of mammalian organs. However, numerous open questions and technical challenges remain to be addressed.
In addition to identifying the most appropriate in vivo cell type sources for lineage reprogramming, it is essential to define the best strategy for the conversion of such cells into the desired cell type. Currently, adenoviral transduction of transcription factor cocktails represents the most common approach for cell reprogramming in vivo. This is associated with a number of issues, including the intrinsic risk of insertional mutations, which represents a major safety concern and severely hinders their clinical applications. Moreover, when the reprogramming process is completed, the endogenous pluripotency programme is normally activated. This means that cells can self-sustain their pluripotent state, with expression of exogenous factors becoming dispensable after about 10 days [139] . Expression of virus-mediated transcription factor, however, is often maintained beyond the reprogramming stage, with unknown consequences.
In other words, viral-induced reprogramming might result in some hurdles for clinical application, and the quest for more appropriate, safer and less-invasive delivery strategies continues.
In this direction, recent studies have shown that pluripotent stem cells can be generated in vitro with minicircle DNA constructs and in vivo via hydrodynamic tail-vein injection of DNA [56] . Additionally, administration of synthetic mRNA could be used to induce not only reprogramming, but also redifferentiation into specific cell types [140] . Sendai virus vectors also represent a valid alternative, as they do not integrate into the genome. They have been used to deliver cardiac reprogramming factors to both rodent and human fibroblasts, efficiently inducing their conversion into cardiomyocytes [141] . Induced cardiomyocytes generated in this way could improve cardiac function and reduce fibrosis in a mouse model of myocardial infarction [141] .
Small molecules represent an even more attractive alternative to transcription factors, as they are generally less expensive, more stable and nonimmunogenic. They can also be more easily synthesised and standardised. Additionally, the administered concentrations and combinations can be fine-tuned and optimised, allowing for a higher degree of spatial and temporal control. Indeed, the use of small molecules for chemical reprogramming could facilitate the removal of the epigenetic barriers that normally act to soundly maintain somatic cell identity. Many interesting small molecules and chemical compounds able to modulate the reprogramming process have already been identified [142] . Furthermore, reprogramming mediated by small molecules could potentially (and attractively) be cell type-specific, introducing the possibility to target specific cell subpopulations of interest. Due to all these advantageous properties, chemical reprogramming could significantly speed up clinical translation of in vivo reprogramming strategies. So far, in an attempt to minimise the number of transgenes required, direct conversion of fibroblasts into cholinergic neurons has been achieved with the combination of a single proneural gene (Neurog2) with the small molecules forskolin and dorsomorphin [143] . Taking these findings one step further, iPSCs were generated from mouse somatic cells using a chemical reprogramming strategy, based on a combination of seven small-molecule compounds without any transgene overexpression [144] . A small molecule was also found to induce an immortalised pancreatic a-cell line to express insulin and convert to a b-cell-like state [145] . Similarly, in vitro, it was possible to achieve chemical-mediated conversion of fibroblasts into both multipotent neural stem cell-like cells and proliferative early cardiac progenitors [146, 147] . When transplanted into the infarcted heart, these cardiac progenitors could survive and develop into cardiomyocytes, smooth muscle cells, and endothelial cells [146, 147] . Furthermore, it has been shown that specific small molecules cocktails can enhance regeneration following acute injury of the liver in vivo [148] . In particular, improved liver function was associated with intraperitoneal administration of a cocktail containing inhibitors of: (a) histone deacetylases (e.g. valproic acid, sodium butyrate); (b) glycogen synthase kinase 3 beta (GSK-3b, e.g. chiron, lithium chloride); (c) transforming growth factor beta (TGF-b, e.g. Repsox, SD-208). Remarkably, cocktails with the same composition are also able to promote reprogramming in vitro [149] . This opens the possibility that the chemical cocktails identified and characterised in vitro could eventually be implemented for reprogramming in vivo. However, the road to in vivo applications is still long and tortuous.
Other additional issues to be overcome include the yield of a number of cells sufficient to mediate functional recovery and, most importantly, the systematic and thorough assessment of the final phenotype obtained. In fact, it is crucial to generate mature cells that are fully converted into the desired cell type, with the ability to successfully and functionally integrate within the host tissue. Among the various tissues and organs, the brain microenvironment seems to be particularly permissive for the survival and maturation of induced neurons. Indeed, it allows for a remarkable level of regenerative plasticity [36, 75, 77] . Notably, extracellular cues of the cortical and striatal microenvironments uniquely instruct non-neuronal cells to adopt distinct neuronal subtypes of varying functional maturity when transduced with Neurog2 [150] . Other microenvironments, however, might not be as favourable.
Overcoming the constraints imposed by the host tissue represents a critical challenge to be addressed in order to promote cellular plasticity. It is therefore important to understand what role the local microenvironment plays, and if there are any specific inhibitory cues that could be removed to boost the endogenous regenerative potential.
Assessing functional maturation also implies ensuring that the newly generated cells will hold no memory of their previous phenotype, so that they do not revert to their original identity. In fact, reprogramming could lead to aberrations in which a cell would have a hybrid epigenetic landscape, with residual elements of the origin cell and functional regions of the adopted identity [142] . We now need to better understand DNA methylation, histone tail marks, three-dimensional chromatin structure and other mechanisms of epigenetic regulation in transdifferentiating and reprogramming cells.
Conclusions and future perspectives
Regenerative capabilities vary extensively across the animal kingdom. Some organisms, such as amphibians and cold-blooded vertebrates, can repair tissues even after massive damage. In humans, there is physiological turnover of cells of the epidermis and intestinal mucosa; apart from this, however, regenerative capability is inherently low and limited to a few tissues, most notably the liver.
Decades of painstaking studies have revealed that successful tissue regeneration involves processes such as dedifferentiation, transdifferentiation, reprogramming and cell fusion. Importantly, these regenerative mechanisms are not mutually exclusive; on the contrary, they could occur independently from each other under different conditions or, alternatively, they could coexist and work synergistically to enhance regeneration.
Various approaches aimed at the enhancement of mammalian regenerative abilities are currently being explored, each one with its own advantages and disadvantages. Such approaches are collectively referred to as regenerative medicine. Regenerative medicine cannot be seen as an isolated, stand-alone science; on the contrary, it relies on contributions from multiple and various fields, ranging from surgery and nanotechnology to tissue engineering, gene therapy and clinical procedures. Among them, induction of in vivo dedifferentiation and reprogramming stands out for its tremendous potential in the clinic.
Nonetheless, numerous questions in the field remain open. For instance, most of the published work has focused on overexpression of pioneering transcription factors. Even though new potential routes for reprogramming are emerging, delivery methods for such factors are, at least for the time being, predominantly viral and, therefore, unsuitable for clinical applications. Additionally, cell identity changes into a specific lineage have been fully accomplished only in vitro.
In our opinion, in vitro studies can (and will) provide valuable insights into the molecular mechanisms and the pathways associated with cell fate and regeneration; however, in order to truly understand the mechanisms controlling pluripotency and reprogramming, more extensive in vivo investigations are required.
To conclude, even though several technical challenges need to be overcome and the feasibility of approaches promoting endogenous repair carefully evaluated, the outcomes of several studies from different fields is slowly, but encouragingly opening up the possibility of using in vivo reprogramming for the treatment of pathologies such as diabetes, muscle degeneration and neurodegenerative diseases. Indeed, in our view, integrating this approach with other aspects of medicine, cell therapy, tissue engineering, molecular medicine and nanotechnology would maximise our chances of achieving satisfactory results in a not-so-distant future.
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